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Objective: To assess the efﬁcacy of long-acting fesoterodine on persistent lower urinary tract symptoms
in men who have had previous surgical treatment for bladder outlet obstruction (BOO).
Materials and methods: Seventeen patients with overactive bladder (OAB) secondary to BOO, persisting
for 3 months after the obstruction was surgically relieved, were treated with fesoterodine. Follow up was
performed at 2 months, 3 months, and 7 months. The primary endpoint was change in the International
Prostate Symptom Score (IPSS). The secondary endpoints were change in the maximum ﬂow rate (Qmax)
and postvoid residual (PVR).
Results: Patients receiving fesoterodine demonstrated trends for improvement in mean nocturia epi-
sodes (3.2e2.6, p ¼ 0.065), IPSS irritative subscore (6.2e2.0, p ¼ 0.066), and quality of life score (4.2e3.5,
p ¼ 0.067) over 7 months of follow up. There was also a reduction in the mean IPSS score which was not
signiﬁcant over time (18.8e15.1, p ¼ 0.183). There was no signiﬁcant change observed in Qmax or PVR.
Six patients (33%) had signiﬁcant side effects and did not complete the study.
Conclusion: Patients with persistent OAB symptoms after surgical treatment of BOO displayed possible
reductions in the IPSS, IPSS irritative subscore, and mean number of nocturia events after 7 months of
follow up, as well as trends for an increased quality of life when treated with fesoterodine. Larger trials
are needed to help characterize the utility of fesoterodine in the treatment of persistent lower urinary
tract symptoms after surgical treatment of benign prostatic hyperplasia.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Transurethral resection of the prostate (TURP) is considered to
be the gold standard in the operative management of benign
prostatic hyperplasia.1e4 Sparked by a desire to improve outcomes
and reduce morbidity and mortality, technological advancements
have increased the surgical options available to patients. However,
even after surgical treatment, as many as one third of patients have
troublesome lower urinary tract symptoms following transurethral
surgery. Incidence of voiding dysfunction after transurethral pros-
tatectomy has been reported to be between 5% and 35%.1
Detrusor overactivity may play a role in the persistent post-
operative symptoms following treatment for bladder outleteill Cornell Medical College,
ghtai).
ciation. Published by Elsevier Taiwobstruction (BOO).5 Although the mechanism is not entirely clear,
studies have shown that the increased bladder pressure often
caused by obstruction can result in denervation of the detrusor
muscle, causing overactivity.6,7 Another cause of detrusor dener-
vation and overactivity can be chronic hypoxia resulting from
decreased blood ﬂow after surgery.8
Persistent LUTS is a difﬁcult problem to manage post TURP. We
investigated the role of antimuscarinics in this setting. The present
study examines the efﬁcacy of antimuscarinic medication fesoter-
odine fumarate (Toviaz, Pﬁzer Inc., New York, NY, USA) for persis-
tent overactive bladder (OAB) symptoms after surgical treatment
for BOO.
2. Materials and methods
After Institutional Review Board approval and informed written
consent were obtained, 18 patients with refractory OAB symptoms
secondary to treatment for BOO participated in this single centeran LLC. Open access under CC BY-NC-ND license.
Table 1
Baseline characteristics.
Age (y) 72.1 (53e91)
BMI (kg/m2) 28.3 (19.1e35.9)
Voided Volume (VV) 86 (20e292)
Procedure
Laser 13 (76.5)
TURP 4 (23.5)
Data are presented as n (%) or median (range).
BMI¼ bodymass index; TURP¼ transurethral resection of the
prostate.
Fig. 1. Change in the International Prostate Symptom Score.
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States Food and Drug Administration approved ﬂexible dosing
regimen of 4e8 mg. The primary endpoint was change in the In-
ternational Prostate Symptom Score (IPSS). The secondary end-
points were change in the maximum ﬂow rate (Qmax), postvoid
residual (PVR), and IPSS quality of life (QoL) score. Follow ups were
performed at 2 months, 3 months, and 7 months post treatment.
Participants were males > 40 years of age who had refractory
OABwith no improvement 3months after TURP. All patients had an
IPSS score > 12 as well as an IPSS QoL score > 3 at screening. At each
postop visit, patients ﬁlled out an American Urological Association
symptom score questionnaire, underwent noninvasive uro-
ﬂowmetry, and had PVR measured by a bladder scan. Patients
completed 3-day bladder diaries between each clinic visit.
Patients with a history of interstitial cystitis, uninvestigated
hematuria, mullerian duct cysts, urethral obstruction caused by
urethral tumor, radiation cystitis, genitourinary tuberculosis,
bladder calculi, or detrusor-sphincter dyssynergia were excluded.
Additional exclusions included evidence of urinary tract infection,
and any signiﬁcant hepatic or renal disease (deﬁned as twice the
upper laboratory limit in AST, ALT, ALP, BUN, or creatinine). Patients
who used any electrostimulation within 30 days of screening,
planned to use electrostimulation, or planned to start any medi-
cation with signiﬁcant anticholinergic, antispasmodic, para-
sympathetic, or cholinergic agonistic effects were also excluded.
Statistical analyses were conducted on an intent-to-treat basis
to evaluate difference of symptoms, PVR, or Qmax from baseline
through 2 months, 3 months, and 7 months follow up. Means and
ranges from raw data are presented. As none of the variables under
consideration are normally distributed, Friedman one-way
nonparametric analysis of variance was used to assess changes
over time. All statistical tests were two-sided and interpreted at a
5% signiﬁcance level; analyses employed the last observation car-
ried forward method. SAS 9.3 (SAS Institute Inc., Cary, NC, USA) was
used for all analyses.3. Results
There were 17 patients enrolled in the trial with a mean age of
72.1 (range 53e91) years and a mean body mass index of 28.25
(range 19.1e35.9). All patients had undergone either TURP orTable 2
Summary of study ﬁndings.a
International Prostate Symptom Score (IPSS)
Time Total Obstructive Irritative Nocturi
0 18.8 (5.3) 9.1 (3.9)b 6.6 (2.1)b 3.2 (1.6
2 15.8 (7.9) 7.5 (5.1) 5.6 (2.6) 2.8 (1.6
3 16.2 (6.3) 8.4 (4.1) 5.1 (2.2) 2.6 (1.3
7 15.1 (6.7) 7.9 (4.3) 4.4 (2.4) 2.6 (1.3
PVR ¼ postvoid residual; QAvg ¼ average ﬂow rate; Qmax ¼ maximum ﬂow rate; QoL ¼
a Data are expressed asmean (standard deviation) at each time period for 17 patients us
b Subscore is missing for one patient.photoselective vaporization of the prostate. Thirteen patients were
treated initially with laser TURP and four with TURP (Table 1).
Eleven of the 17 patients enrolled completed the full 7 months. Six
patients were unable to complete the 7-month trial period because
of medication related adverse effects. Adverse effects leading to
withdrawal from the study included constipation in three patients
(17% of total enrolled), dry mouth in three patients (17%), and dry
eyes in one patient (6%).
There was a trend for reductions observed in mean nocturia
episodes (3.2e2.6, p ¼ 0.065) and the IPSS irritative subscore
(6.2e2, p ¼ 0.066) and QoL score (4.2e3.5, p ¼ 0.067) over the 7
months of follow up (Table 2). There was also a reduction in the
mean IPSS score which was not signiﬁcant over time (18.8e15.1,
p ¼ 0.183; Table 2). There was no signiﬁcant change observed in
Qmax or PVR.
To our knowledge, there has been no other study on the use of
fesoterodine for the treatment of refractory OAB after TURP. The use
of fesoterodine demonstrated possible reductions in the IPSS, IPSS
irritative subscore, and mean number of nocturia events after 7
months of follow up (Table 2; Fig. 1). There were also trends for an
increased quality of life (a lower QoL score indicating a more pos-
itive outlook; Table 2). The IPSS obstructive subscore did decrease
in a similarly continuous manner over 7 months, but this was not
found to be statistically signiﬁcant (Fig. 1; Table 2). Change in PVR
after 7monthswas not statistically signiﬁcant. As seen in Fig. 2, PVR
appears to drop and increase again after 2 months, whereas Qmax
appears steady over time. Of the nine patients who remained on the
trial for the full 7 months, seven patients continued treatment long
term for > 15 months.
4. Discussion
Treatment with fesoterodine was tolerated in our small cohort.
Six patients withdrew from the study due to side effects associated
with fesoterodine, mainly constipation and severe dry mouth. NoUrodynamics
a QoL Qmax QAvg PVR
)b 4.2 (1.1) 15.3 (18.0) n/a 42.9 (43.2)
) 3.8 (1.3) 10.2 (3.5) 5.1 (2.0) 33.1 (39.4)
) 3.5 (1.5) 10.6 (3.9) 6.1 (2.6) 48.2 (64.8)
) 3.5 (1.5) 10.5 (4.2) 6.2 (3.0) 55.2 (56.1)
quality of life.
ing the last observation carried forward for six patients who dropped out of the trial.
Fig. 2. Changes in postvoid residual (PVR) and maximum ﬂow rate (Qmax).
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responds to that shown by both Chapple et al9 and Nitti et al.1
Konstantinidis et al10 conducted a randomized prospective
study comparing fesoterodine extended-release in combination
with tamsulosin to tamsulosin alone, for 47 men with persistent
OAB after 1 week of tamsulosin. Patients who received the addition
of fesoterodine displayed signiﬁcantly reduced troublesome LUTS
and storage symptoms after 4 weeks as measured by IPSS.10 In a
double-blind placebo controlled study conducted by Weiss et al,11
the use of fesoterodine for overactive bladder symptoms, particu-
larly nocturnal urinary urgency, resulted in reduced micturition-
related nocturnal urgency episodes. This corresponds to our ﬁnd-
ings of decreased mean nocturia episodes over 7 months. In a
subanalysis of pooled data enrolled in two double-blind, placebo-
controlled Phase III trials, Herschorn et al12 found fesoterodine
4 mg and 8 mg to be effective for overactive bladder symptoms in
358 men. It was well tolerated with the side effects consisting of
mainly constipation and dry mouth.
This pilot study has several limitations. These include small
study size and the nonrandomized and nonblinded administration
of the drug. Also, patients may have had some resolution of their
irritative symptoms over time. The inclusion of several different
surgical procedures in a small cohort of patients creates the po-
tential for a different incidence of postoperative OAB and different,
time-dependent, self-limiting storage symptoms.
This study was conducted using 3-day voiding diaries. Although
consistent withmost other trials, a 7-day diarymay have unmasked
other changes in voiding habits, incontinence episodes, etc. Larger
trials that are both randomized and blinded are needed to further
characterize the role of fesoterodine in the cohort.
5. Conclusion
The use of the antimuscarinic medication fesoterodine fumarate
demonstrated possible reductions in the IPSS, IPSS irritative sub-
score, andmean number of nocturia events after 7months of follow
up, as well as trends for an increased quality of life (a lower score
indicating a more positive outlook) in our small cohort of patientswith refractory OAB after surgical treatment for benign prostatic
hyperplasia. There was a dropout rate of 33%. Additional larger
trials are needed to further analyze the utility of fesoterodine for
this difﬁcult-to-manage indication in this cohort.
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